BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:
A replay of all webcasts will be available on-demand on the Albireo Investors page ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today issued the following statement to set the record straight…
Innovation Leaders in Technology-Enabled Care, Careium, and Critical Connectivity Experts, CSL, have announced the extension…
Dagfinn Hallseth, CEO and founder of NEO Consulting AS, has been awarded the title of…
NEURIED, Germany, June 20, 2024 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), a frontrunner in advanced biomaterials…
Drs. Marko Radic and Georg Schett Honored at FOCIS 2024 Meeting SAN FRANCISCO, June 20,…
HONG KONG and SHANGHAI, June 20, 2024 /PRNewswire/ -- Institutional Investor magazine has announced the…